Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.
Apostolia-Maria TsimberidouHenry Hiep VoVivek SubbiahFilip JankuSarina Piha-PaulBulent YilmazJing GongMohammad Faraz NaqviShi-Ming TuMatthew CampbellFunda Meric-BernstamAung NaingPublished in: The oncologist (2021)
Overall, pembrolizumab was safe and had limited antitumor activity in these patients. In the advanced, metastatic setting, tumor profiling to understand the mechanisms of resistance to immunotherapy and innovative clinical trials to identify efficacious combination regimens rather than off-label use of pembrolizumab are warranted.
Keyphrases
- clinical trial
- advanced non small cell lung cancer
- end stage renal disease
- squamous cell carcinoma
- germ cell
- small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- patient reported outcomes
- epidermal growth factor receptor
- study protocol
- tyrosine kinase